Case study Neuroleptic malignant syndrome induced by haloperidol following traumatic brain injury

References

• INTERAGENCY HEAD INJURY TASK FORCE: Report, National Institute of Neurological Disorders and Stroke, National Institutes of Health. Bethesda, MD, February 1989.
   Google Scholar
• ADAMS, J. H., MITCHELL, D. E., GRAHAM, D. I. et al.: Diffuse brain damage of immediate impact type: Its relationship to primary brain-stem damage in head injury. Brain, 100: 489–502,1977.
   PubMed Web of Science ®Google Scholar
• ADAMS, J. H., DOYLE, D., FORD, I. et al.: Diffuse axonal injury in head injury: Definition, diagnosis and grading. Histopathology, 15: 459,1989.
   Google Scholar
• MCLELLAN, D. R.: The structural bases of coma and recovery: Insights from brain injury in humans and experimental animals. Physical Medicine Rehabilitation Reviews, 4: 389–407,1990.
   Google Scholar
• POVLISHOCK, J. T.: Pathobiology of traumatically induced axonal injury in animals and man. Annals of Emergency Medicine, 22: 980–986,1993.
   PubMed Web of Science ®Google Scholar
• MOINToSH,T. K., VINK, R., SOARES, H. et al.: Effects of N-Methyl-D-Aspartate receptor blocker MK-801 on neurologic function after experimental brain injury. Journal of Neurotrauma, 6: 247–259,1989.
   PubMedGoogle Scholar
• LINDSAY, K. W., BONE, I. and CALLENDER, R.: Neurology and Neurosurgery Illustrated, 2nd Edn (New York: Churchill Livingstone), pp 141–199,1991.
   Google Scholar
• EVANS, R. W. and GUALTIERI, C. T.: Psychostimulant pharmacology in traumatic brain injury. Journal of Head Trauma Rehabilitation, 2: 29–33,1987.
   Google Scholar
• ROSS, E. D. and STEWART, R. M.: Akinetic mutism from hypothalamic damage: Successful treatment with dopamine agonist. Neurology, 31: 1435–1439,1981.
   PubMed Web of Science ®Google Scholar
• WHYTE, J. and ROSENTHAL, M.: Rehabilitation of the patient with traumatic brain injury. In J. A. DeLisa (editor) Rehabilitation Medicine: Principles and Pratice, 2nd Edn (Philadelphia: Lippincott Company), pp. 825–860,1993.
   Google Scholar
• AUERBACH, S. H.: Neuroanatomical correlates of attention and memory disorders in traumatic brain injury: An application of behavioral subtypes. Journal of Head Trauma Rehabilitation, 1: 1–12, 1986.
   Google Scholar
• CARDENAS, D. D. and MCLEAN, JR A.: Psychopharrnacolgic management of traumatic brain injury. Physical Medicine and Rehabilitation Clinics of North America, 3: 273,1992.
   Google Scholar
• FEENEY, D. M., GONZALEZ, A. and LAW,W. A.: Amphetamine, haloperidol and experience interact to affect rate of recovery after motor cortex surgery. Science, 217: 855–857,1982.
   Google Scholar
• VAN HASSELT, P.: Effect of butyrophenones on motor function in rats after recovery from brain damage. Neuropharmacology, 12: 245–247,1973.
   PubMed Web of Science ®Google Scholar
• DELAY, J., PICOT, P., LEMPERIER, M. T. et al. Un neuroleptique majeur non phenothiazineque et non reserpinique, l'halidol, dans le traitement des psychoses. Annals of Medical Psychology (Paris), 118: 145–152,1960.
   PubMedGoogle Scholar
• BOURGEOIS, M., TIGNOL, J. and DEBoucHARD, D.: Le syndrome malin des neuroleptiques. Bordeaux Medicine, 4: 1115–1128,1971.
   PubMedGoogle Scholar
• KELLAM, A. M.: The neuroleptic malignant syndrome, so-called--a survey of the world literature. British Journal of Psychiatry, 150: 752–759,1987.
   PubMedGoogle Scholar
• MYERS, F. H.: Benign type of malignant syndrome. Lancet, I: 50,1989.
   Google Scholar
• KELLUM, A. M. P.: The (frequently) neuroleptic (potentially) malignant syndrome. British Journal of Psychiatry, 157: 16–17,1990.
   Google Scholar
• BRISTOW, M. F. and KOHEN, D.: How 'malignant' is the neuroleptic malignant syndrome? British Medical Journal, 307: 1223–1224,1993.
   Google Scholar
• CAROFF, S. N. and MANN, S. C.: Neuroleptic malignant sydrome. Medical Clinics of North America, 71: 185–202,1993.
   Google Scholar
• SHALEV, A. and MUNITZ, H.: The neuroleptic malignant syndrome: Agent and host interation. Acta Psychiatrica Scandinavica, 73: 337–347,1986.
   PubMed Web of Science ®Google Scholar
• GELENBERG, A. J., BELLINGHAusEN B., WOJCIK, J. D. et al.: A prospective survey of neuroleptic malignant syndrome in a short-term psychiatric hospital. American L Psychiatry, 145: 517–518, 1988.
   Google Scholar
• KECK, P. E., POPE, H. G. and MCELROY, S. I.: Declining frequency of neuroleptic malignant syndrome in a hospital population. American Journal of Psychiatry, 148: 880–882,1991.
   PubMedGoogle Scholar
• HENDERSON,V. W. and WOOTEN, G. F.: Neuroleptic malignant syndrome: A pathophysiologic role for the dopamine receptor blockade? Neurology, 1331: 1495–1497,1981.
   Google Scholar
• KECK, P. E., POPE, H. G., COHEN, B. M. et al.: Risk factors for neuroleptic malignant syndrome. Archives of General Psychiatry, 46: 914–918,1989.
   PubMed Web of Science ®Google Scholar
• ROSEBUSH, PT. and STEWART, T. A.: Prospective analysis of 24 episodes of neuroleptic malignant syndrome. American Journal of Psychiatry, 146: 717–725,1989.
   Google Scholar
• ADAMS, R. D. and VICTOR, M.: Principles of Neurology, 5th Edn (New York: McGraw-Hill Inc), pp. 934–935,1993.
   Google Scholar
• Diagnostic and Statistical Manual for Mental Disorders. 4th edn (DSM-IV) (Washington DC: American Psychiatric Press), pp. 739–742,1994.
   Google Scholar
• BAREGGI, S. R. et al.: HVA and %-HIAA in CSF of patients after severe head injury syndrome. European Neurology, 13: 528–544,1975.
   PubMedGoogle Scholar
• KRAUS, M. F. and MAKI, P.: The combined use of Amantadine and 1-dopa/carbidopa in the treatment of chronic brain injury. Brain Injury, 11: 455–460,1997.
   Google Scholar
• VANWOERKOM, T. C. A. M., TEELKEN, A. W. and MEINDERHOUD, J. M.: Difference in neurotrans-mitter metabolism in frontotemporal-lobe contusion and diffuse cerebral contusion. Lancet, 1: 812–813,1977.
   Google Scholar
• VANWOERKOM, M.: Pharrnacologic Interventions. PM&R Reviews, 4: 447–464,1990.
   Google Scholar
• SNYDER, S. H., GREENBERG, D. and YAMANURA, H.: Anti-schizophrenic drugs and brain choli-nergic receptors. Archives of General Psychiatry, 31: 58–61,1974.
   PubMed Web of Science ®Google Scholar
• ADELOY, A.: Clinical trial of fluphenazine in the postconcussional syndrome. Practioner, 206: 517–519,1971.
   PubMedGoogle Scholar
• VASCONCELLOS, J.: Clinical evaluation of trifluoperazine in maximum-security brain damaged patients with an organic brain disorder. JAMA, 240: 380–382,1978.
   PubMedGoogle Scholar
• KAPLAN H. I. and SADOCK, B. J. (editors) Pocket Handbook of Psychiatric Drug Treatment: dopamine receptor antagonist: antipsychotics (Baltimore: Williams and Wilkins), pp. 104–131,1993.
   Google Scholar
• REINHARD, M., DOUGHTERY, A. and SANDEL, M.: Improved arousal and initiation following tricyclic antidepressant use in traumatic brain injury. Archives of Physical Medicine & Rehabilitation, 77: 80–83,1996.
   PubMed Web of Science ®Google Scholar
• KAEUN, D., WHYTE, J. and SANDEL, M.: Methylphenidate effect on attention deficit in the acutly brain injured adult study. Archives of Physical Medicines& Rehabilitation, 77: 6–9,1996.
   PubMedGoogle Scholar
• PLENGER, P.: Subacute methylphenidate treatment for moderate to moderately severe traumatic brain injury: a preliminary double blind study. Archives of Physical Medicine & Rehabilitation, 77: 536–540,1996.
   PubMed Web of Science ®Google Scholar
• SAKICAS, P., DAVIS, J. M., HUA, J. et al.: Pharrnacotherapy of neuroleptic malignant syndrome. Psychiatry Annals, 21: 157–164,1991.
   Google Scholar
• MOONEY, R. P. and HASAN, M. K.: Neuroleptic malignant syndrome. W V Medical Journal, 86: 95–98,1990.
   PubMedGoogle Scholar
• BROOKE, M. M., PATTERSON, D. R., QUESTAD, K . A. et al.: The treatment of agitation during initial hospitalization after traumatic brain injury. Archives of Physical Medicine & Rehabilitation, 73: 917–921,1992.
   Google Scholar
• MEYTHALER, J. M. and STINSON, A. M.: Fever of central origin in traumatic brain injury controlled with propanolol. Archives of Physical Medicine & Rehabilitation, 75: 816–818,1994.
   PubMed Web of Science ®Google Scholar
• VAN REEKUM, R.: N of 1 study; Amantadine for a motivational syndrome in a patient with traumatic brain injury. Brain Injury, 9: 49–53,1995.
   Google Scholar
• NICKELS, J., SCHNIEDER, W., DOMBROVY, M. et al.: Clinical use of Amantadine in brain injury rehabilitation. Brain Injury, 8: 809–818,1994.
   Google Scholar
• ZAFONTE, R. D., WATANABE, T. and MANN, N. R. :Amantadine: A potential treatment for the minimally conscious state. Brain Injury, 12: 617–621,1998.
   PubMed Web of Science ®Google Scholar
• VAN HASSELT, P.: Effect of butyrophenones on motor function in rats after recovery from brain damage. Neuropharmacology, 12: 245–247,1973.
   PubMed Web of Science ®Google Scholar